Semaglutide vs. Bariatric Surgery for Liver Disease

Key Finding Liver stiffness improvement did not differ significantly between semaglutide and surgery despite surgery producing three times more weight loss, and the semaglutide effect appeared independent of weight change.

A new observational study in the Journal of Clinical Endocrinology & Metabolism compares three ways of treating obesity-related liver disease head to head: lifestyle change, semaglutide, and bariatric surgery. The question matters because metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by obesity, and both pharmacology and surgery are now realistic options [PMID 42657770].

What the study did

The authors followed 92 adults with obesity for 72 weeks in a single-center, prospective cohort. Patients received one of three approaches: a lifestyle-based multimodal program (n = 30), lifestyle plus once-weekly semaglutide at roughly 1 mg (n = 30), or lifestyle plus laparoscopic sleeve gastrectomy (n = 32). Liver status was tracked with FibroScan — the controlled attenuation parameter (CAP) for steatosis and liver stiffness measurement (LSM) for fibrosis — plus the FIB-4 and FAST scores.

Everyone in the study had hepatic steatosis at baseline.

What it found

All three groups moved in the right direction, but not equally. CAP fell by about 18 dB/m with lifestyle alone, 46 dB/m with semaglutide, and 84 dB/m after surgery. Liver stiffness declined in the semaglutide and surgery groups roughly three to six times as much as with lifestyle alone — and notably, the relative reduction between semaglutide and surgery was not statistically different (p = 0.428). Weight loss, by contrast, was very different: roughly 4 percent with lifestyle, 11 percent with semaglutide, and 32 percent with surgery.

The curiosity sits right there. Surgery produced about three times the weight loss of semaglutide but did not produce a significantly better liver-stiffness outcome on adjusted analysis. In the surgery group, stiffness improvement tracked weight loss; in the semaglutide group it did not. The authors call the finding hypothesis-generating and point to possible weight-independent mechanisms — direct hepatic effects, or anti-inflammatory changes that run parallel to weight reduction.

One caution flag appeared as well: FIB-4, a marker that can reflect fibrosis progression, rose modestly after surgery (+0.29) while remaining stable in the semaglutide and lifestyle groups. The authors flag this as something to watch rather than a settled interpretation.

Why this is worth a second read

This is not a randomized trial. It is a single-center observational cohort with three self-selected treatment groups, which means the usual confounders — who chooses surgery, who tolerates an injection, who can sustain lifestyle work — sit between the reader and the numbers. The imaging markers are validated surrogates, but they are not liver biopsy histology.

Even with those limits, the study earns attention because of the comparison itself. Most of the MASLD literature evaluates one intervention against placebo or usual care. A direct pharmacological-versus-surgical comparison on the same follow-up protocol is less common, and the finding that adjusted liver stiffness ended up comparable across a wide weight-loss gap is exactly the kind of result that generates better-designed trials. For anyone tracking semaglutide’s clinical footprint — or the incretin class more broadly — the liver is increasingly part of the story.

For a complete reference record on semaglutide, including preparation and administration notes, see the Semaglutide reference record on ResearchProtocols.